Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

BJU International

Volumn 106, Issue 6, 2010, Pages 772-778

  Choueiri, Toni K ^a   Regan, Meredith M ^a   Rosenberg, Jonathan E ^a   Oh, William K ^a   Clement, Jessica ^a   Amato, Angela M ^a   McDermott, David ^a   Cho, Daniel C ^a   Atkins, Michael B ^a   Signoretti, Sabina ^a,b  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

carbonic anhydrase IX; pathological features; renal cell cancer; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; SORAFENIB; SUNITINIB; TUMOR MARKER; VASCULOTROPIN; VATALANIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CA9 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CARBONATE DEHYDRATASE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR ANTIGEN; TUMOR PROTEIN; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; ENZYMOLOGY; EPIDEMIOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRIDINES; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956198463     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09218.x     Document Type: Article

References (20)

1. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001 19 : 148 154
2. Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 2006 33 : 596 606
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 134
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124
5. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004 10 : 6367S 670S
6. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005 41 : 2935 2947
7. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003 9 : 802 811
8. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005 11 : 3714 3721
9. Di Napoli A, Grisanzio C, Ghebremichael M et al. CAIX expression correlates with VHL mutational status in sporadic clear cell carcinoma of the kidney. Annual Meeting United States and Canadian Division of the International Academy of Pathology, Denver, Colorado 2008
10. Patard JJ, Fergelot P, Karakiewicz PI et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008 123 : 395 400
11. Choueiri TK, Vaziri SA, Jaeger E et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008 180 : 860 865
12. Patel PH, Chadalavada RS, Ishill NM et al. Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008 26 : Abstract 5008
13. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005 28 : 488 495
14. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002 20 : 2376 2381
15. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in metastatic clear-cell renal cell carcinoma patients treated with VEGF-targeted therapy. Cancer 2007 110 : 543 550
16. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993 54 : 268 274
17. Atkins MB, Ernstoff MS, Figlin RA et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007 13 : 667s 670s
18. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 370 : 2103 11
19. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 20 : 289 296
20. Signoretti S, Atkins M. CAIX and the treatment of metastatic clear cell: carcinoma. Presented at the First International CA-IX Symposium, Brussels, Belgium. November 14, 2007